AMF Tjanstepension AB Purchases 154,530 Shares of Gilead Sciences, Inc. $GILD

AMF Tjanstepension AB raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 41.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 524,960 shares of the biopharmaceutical company’s stock after purchasing an additional 154,530 shares during the period. AMF Tjanstepension AB’s holdings in Gilead Sciences were worth $58,244,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Southland Equity Partners LLC grew its stake in shares of Gilead Sciences by 2.9% in the 2nd quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock worth $364,000 after acquiring an additional 92 shares in the last quarter. Twelve Points Wealth Management LLC lifted its position in shares of Gilead Sciences by 1.5% during the second quarter. Twelve Points Wealth Management LLC now owns 6,499 shares of the biopharmaceutical company’s stock valued at $721,000 after purchasing an additional 98 shares in the last quarter. Argentarii LLC boosted its holdings in Gilead Sciences by 3.0% during the first quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company’s stock worth $380,000 after purchasing an additional 99 shares during the last quarter. Perkins Coie Trust Co grew its position in Gilead Sciences by 2.6% in the 1st quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company’s stock worth $435,000 after purchasing an additional 100 shares in the last quarter. Finally, Investment Research & Advisory Group Inc. increased its stake in Gilead Sciences by 33.3% in the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 100 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently weighed in on GILD. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a research note on Saturday, September 27th. Rothschild & Co Redburn lifted their price target on Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Needham & Company LLC raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price objective on the stock in a research report on Friday, July 25th. UBS Group raised their target price on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research report on Friday, August 8th. Finally, Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $117.17.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the transaction, the chief financial officer owned 159,555 shares in the company, valued at $18,120,661.35. This trade represents a 1.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the transaction, the insider directly owned 114,168 shares of the company’s stock, valued at $13,532,333.04. The trade was a 19.70% decrease in their position. The disclosure for this sale can be found here. Insiders sold 82,000 shares of company stock valued at $9,402,130 over the last three months. Insiders own 0.27% of the company’s stock.

Gilead Sciences Trading Up 1.9%

Shares of Gilead Sciences stock opened at $112.69 on Friday. The stock has a market capitalization of $139.83 billion, a P/E ratio of 22.45, a P/E/G ratio of 0.75 and a beta of 0.34. Gilead Sciences, Inc. has a 52-week low of $83.98 and a 52-week high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The stock’s 50-day simple moving average is $114.34 and its 200 day simple moving average is $109.92.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. During the same quarter last year, the company earned $2.01 earnings per share. The company’s revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were given a dividend of $0.79 per share. The ex-dividend date was Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. Gilead Sciences’s dividend payout ratio is currently 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.